STOCK TITAN

[144] Eli Lilly & Co. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Form 144 notice for Eli Lilly & Co. (LLY) reports a proposed sale of 2,000 common shares through Morgan Stanley Smith Barney LLC on 08/28/2025 on the NYSE with an aggregate market value of $1,468,340.00. The shares were acquired as Restricted Stock Units on 02/09/2022 from the issuer and payment information is listed as N/A.

The filer reports no securities sold during the past three months. The form includes the standard representation that the selling person is not aware of undisclosed material adverse information and provides space for signature and plan-adoption dates, but those fields are not populated in the supplied content.

Avviso Form 144 per Eli Lilly & Co. (LLY) segnala una proposta di vendita di 2.000 azioni ordinarie tramite Morgan Stanley Smith Barney LLC in data 28/08/2025 sul NYSE, per un valore complessivo di mercato di $1.468.340,00. Le azioni sono state acquisite come Restricted Stock Units il 09/02/2022 dall'emittente e le informazioni sul pagamento risultano N/A.

Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi. Il modulo include la dichiarazione standard che la persona che vende non è a conoscenza di informazioni materiali sfavorevoli non divulgate e prevede spazi per firma e date di adozione del piano, ma tali campi non sono compilati nel contenuto fornito.

Aviso Formulario 144 para Eli Lilly & Co. (LLY) informa sobre una propuesta de venta de 2.000 acciones ordinarias a través de Morgan Stanley Smith Barney LLC el 28/08/2025 en la NYSE, con un valor de mercado agregado de $1,468,340.00. Las acciones fueron adquiridas como Restricted Stock Units el 09/02/2022 del emisor y la información de pago aparece como N/A.

El declarante indica que no ha vendido valores en los últimos tres meses. El formulario incluye la representación estándar de que la persona vendedora no conoce información material adversa no divulgada y dispone de espacios para la firma y las fechas de adopción del plan, pero esos campos no están completados en el contenido suministrado.

Eli Lilly & Co. (LLY) 관련 Form 144 통지는 NYSE에서 2025-08-28에 Morgan Stanley Smith Barney LLC를 통해 2,000 보통주를 매도할 예정이며 총 시가총액은 $1,468,340.00라고 보고합니다. 해당 주식은 발행인으로부터 2022-02-09Restricted Stock Units으로 취득되었고 결제 정보는 N/A로 기재되어 있습니다.

신고자는 최근 3개월 동안 매도한 증권이 없음을 보고합니다. 양식에는 매도인이 공개되지 않은 중대한 불리한 정보를 알고 있지 않다는 표준 진술과 서명 및 플랜 채택일을 기재하는 란이 포함되어 있으나, 제공된 내용에서는 해당 항목들이 채워져 있지 않습니다.

Avis Formulaire 144 pour Eli Lilly & Co. (LLY) signale une proposition de vente de 2 000 actions ordinaires via Morgan Stanley Smith Barney LLC le 28/08/2025 sur le NYSE, pour une valeur de marché globale de 1 468 340,00 $. Les actions ont été acquises en tant que Restricted Stock Units le 09/02/2022 auprès de l'émetteur et les informations de paiement sont indiquées comme N/A.

Le déposant déclare n'avoir vendu aucun titre au cours des trois derniers mois. Le formulaire inclut la déclaration standard selon laquelle la personne vendant n'a pas connaissance d'informations défavorables importantes non divulguées et prévoit des champs pour la signature et les dates d'adoption du plan, mais ces champs ne sont pas renseignés dans le contenu fourni.

Form 144-Mitteilung für Eli Lilly & Co. (LLY) meldet einen geplanten Verkauf von 2.000 Stammaktien über Morgan Stanley Smith Barney LLC am 28.08.2025 an der NYSE mit einem Gesamtmarktwert von $1.468.340,00. Die Aktien wurden am 09.02.2022 als Restricted Stock Units vom Emittenten erworben; Angaben zur Zahlung sind mit N/A vermerkt.

Der Einreicher gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben. Das Formular enthält die übliche Erklärung, dass die verkaufende Person keine nicht offengelegten, wesentlichen nachteiligen Informationen kenne, und Felder für Unterschrift und Datum der Planannahme, die im vorliegenden Inhalt jedoch nicht ausgefüllt sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine insider sale notice for 2,000 RSU-derived shares valued at $1.47M; no recent sales reported.

The filing documents a proposed sale under Rule 144 of 2,000 common shares acquired as restricted stock units on 02/09/2022. The sale is scheduled through Morgan Stanley Smith Barney LLC on 08/28/2025 at the NYSE and shows an aggregate market value of $1,468,340.00. The disclosure that no shares were sold in the prior three months limits concerns about recent disposition activity. The form does not include the seller's identity, plan-adoption date, or signature in the provided text.

TL;DR: Compliance-focused filing; it contains required representations but lacks populated signature or plan-adoption details in the excerpt.

The submission appears to fulfill Rule 144 procedural disclosure by identifying the broker, class, quantity, acquisition type, and planned sale date. It reiterates the seller's representation regarding material nonpublic information and references Rule 10b5-1 planning, but the provided content does not show a signed attestation or a 10b5-1 adoption date. Those missing elements are notable for completeness but are not unusual in partial extracts.

Avviso Form 144 per Eli Lilly & Co. (LLY) segnala una proposta di vendita di 2.000 azioni ordinarie tramite Morgan Stanley Smith Barney LLC in data 28/08/2025 sul NYSE, per un valore complessivo di mercato di $1.468.340,00. Le azioni sono state acquisite come Restricted Stock Units il 09/02/2022 dall'emittente e le informazioni sul pagamento risultano N/A.

Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi. Il modulo include la dichiarazione standard che la persona che vende non è a conoscenza di informazioni materiali sfavorevoli non divulgate e prevede spazi per firma e date di adozione del piano, ma tali campi non sono compilati nel contenuto fornito.

Aviso Formulario 144 para Eli Lilly & Co. (LLY) informa sobre una propuesta de venta de 2.000 acciones ordinarias a través de Morgan Stanley Smith Barney LLC el 28/08/2025 en la NYSE, con un valor de mercado agregado de $1,468,340.00. Las acciones fueron adquiridas como Restricted Stock Units el 09/02/2022 del emisor y la información de pago aparece como N/A.

El declarante indica que no ha vendido valores en los últimos tres meses. El formulario incluye la representación estándar de que la persona vendedora no conoce información material adversa no divulgada y dispone de espacios para la firma y las fechas de adopción del plan, pero esos campos no están completados en el contenido suministrado.

Eli Lilly & Co. (LLY) 관련 Form 144 통지는 NYSE에서 2025-08-28에 Morgan Stanley Smith Barney LLC를 통해 2,000 보통주를 매도할 예정이며 총 시가총액은 $1,468,340.00라고 보고합니다. 해당 주식은 발행인으로부터 2022-02-09Restricted Stock Units으로 취득되었고 결제 정보는 N/A로 기재되어 있습니다.

신고자는 최근 3개월 동안 매도한 증권이 없음을 보고합니다. 양식에는 매도인이 공개되지 않은 중대한 불리한 정보를 알고 있지 않다는 표준 진술과 서명 및 플랜 채택일을 기재하는 란이 포함되어 있으나, 제공된 내용에서는 해당 항목들이 채워져 있지 않습니다.

Avis Formulaire 144 pour Eli Lilly & Co. (LLY) signale une proposition de vente de 2 000 actions ordinaires via Morgan Stanley Smith Barney LLC le 28/08/2025 sur le NYSE, pour une valeur de marché globale de 1 468 340,00 $. Les actions ont été acquises en tant que Restricted Stock Units le 09/02/2022 auprès de l'émetteur et les informations de paiement sont indiquées comme N/A.

Le déposant déclare n'avoir vendu aucun titre au cours des trois derniers mois. Le formulaire inclut la déclaration standard selon laquelle la personne vendant n'a pas connaissance d'informations défavorables importantes non divulguées et prévoit des champs pour la signature et les dates d'adoption du plan, mais ces champs ne sont pas renseignés dans le contenu fourni.

Form 144-Mitteilung für Eli Lilly & Co. (LLY) meldet einen geplanten Verkauf von 2.000 Stammaktien über Morgan Stanley Smith Barney LLC am 28.08.2025 an der NYSE mit einem Gesamtmarktwert von $1.468.340,00. Die Aktien wurden am 09.02.2022 als Restricted Stock Units vom Emittenten erworben; Angaben zur Zahlung sind mit N/A vermerkt.

Der Einreicher gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben. Das Formular enthält die übliche Erklärung, dass die verkaufende Person keine nicht offengelegten, wesentlichen nachteiligen Informationen kenne, und Felder für Unterschrift und Datum der Planannahme, die im vorliegenden Inhalt jedoch nicht ausgefüllt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for LLY report?

It reports a proposed sale of 2,000 common shares acquired as Restricted Stock Units on 02/09/2022, to be sold on 08/28/2025 with aggregate market value $1,468,340.00.

Through which broker will the LLY shares be sold?

The filing lists Morgan Stanley Smith Barney LLC as the broker, with an indicated NY address and execution on the NYSE.

Were any LLY securities sold by the person in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months.

How were the shares being sold acquired?

The shares were acquired as Restricted Stock Units from the issuer on 02/09/2022.

Does the filing show a signed attestation or 10b5-1 plan date?

In the provided content, signature and plan-adoption/instruction date fields are not populated.
Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Latest News

LLY Latest SEC Filings

LLY Stock Data

659.82B
944.35M
0.16%
83.87%
0.8%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS